Revance Therapeutics, Inc. (RVNC) has 61 open-market insider trades by 16 insiders since 2014. The most active filer is L. Daniel Browne, CEO & President.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Mark J. Foley | CEO | — | 5 | $10.6M | 2025-02-06 |
| Aubrey Rankin | Pres | — | 10 | $9.1M | 2022-03-15 |
| L. Daniel Browne | CEOPres | — | 15 | $4.2M | 2019-06-28 |
| Dwight Moxie | VPSecretary | — | 5 | $3.0M | 2025-02-06 |
| Tobin Schilke | CFO | — | 5 | $2.9M | 2025-02-06 |
| Dustin S. Sjuts | Pres | — | 3 | $2.9M | 2024-03-18 |
| Lauren P. Silvernail | CFO | — | 8 | $2.3M | 2018-05-22 |
| Jacob Waugh | Chief Scientific Officer | — | 1 | $612K | 2015-05-19 |
| Phyllis Gardner | Dir | — | 1 | $336K | 2020-05-14 |
| Arthur Peter Bertolino | EVP and Chief Medical Officer | — | 1 | $303K | 2015-11-17 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| David Hollander | CMO & Global Therapeutics Lead | Sell | $16K | 2024-11-18 |
| Erica Jordan | Chief Commercial Officer | Sell | $9K | 2024-04-16 |
| Dwight Moxie | CLO & GC | Sell | $41K | 2024-03-18 |
| Tobin Schilke | CFO | Sell | $47K | 2024-03-18 |
| Dustin S. Sjuts | President | Sell | $46K | 2024-03-18 |
| Mark J. Foley | CEO | Buy | $209K |
Companies that share insiders with RVNC, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2024-03-06 |
| Dwight Moxie | VP & Secretary | Sell | $1.0M | 2023-09-05 |
| Mark J. Foley | CEO | Sell | $1.2M | 2023-08-03 |
| Mark J. Foley | CEO | Sell | $1.3M | 2023-07-03 |
| Tobin Schilke | CFO | Sell | $43K | 2023-07-03 |
| Carey OConnor Kolaja | Director | Sell | $71K | 2023-06-15 |
| Dustin S. Sjuts | President | Sell | $154K | 2023-06-09 |
| Mark J. Foley | CEO | Sell | $1.9M | 2023-06-09 |
| Tobin Schilke | CFO | Sell | $181K | 2023-06-01 |
| Dwight Moxie | VP & Secretary | Sell | $1.5M | 2023-05-15 |